Dual inhibition of EGFR and PI3K with a single drug

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-08-16 DOI:10.1038/s43018-024-00806-0

Meghri Katerji, Maxine R. Rubin, John Brognard

引用次数: 0

Abstract

Precision medicine holds immense promise for treating individuals with cancer. A new study unveils MTX-531 — a drug that can inhibit two signaling proteins, EGFR and PI3K — which was developed through innovative computational drug design and offers new hope for more-effective and better-tolerated cancer treatments.

Abstract Image

查看原文本刊更多论文

用一种药物同时抑制表皮生长因子受体和 PI3K。

精准医疗为治疗癌症患者带来了巨大希望。一项新的研究揭示了 MTX-531--一种可以抑制表皮生长因子受体和 PI3K 这两种信号蛋白的药物--它是通过创新的计算药物设计开发出来的，为更有效、耐受性更好的癌症治疗带来了新的希望。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.